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This reply refers to Weber S, Pongratz G,
Schneider M, Brinks R Need for improvements
in reported cost-eﬀectiveness of adalimumab
in rheumatoid arthritis. doi:10.1007/s00393-
016-0255-3
Original version: Gissel, Götz, Repp (2016)
Cost-eﬀectiveness of adalimumab for
rheumatoid arthritis in Germany. doi:10.
1007/s00393-016-0071-9
We thank Sergej Weber, Georg Pongratz,
Matthias Schneider and Ralph Brinks for
acknowledging the relevance of health
economic modeling for biologic treat-
ments for rheumatoid arthritis. We take
this opportunity to comment on some
health economic concepts that ourmodel
is based on:
1. Concerning transition probabili-
ties: We set up an individual patient
sampling model that simulates each
patient individually based on the
treatment algorithms and the spe-
ciﬁc treatment duration parameters
as speciﬁed or cited in the paper’s
“Model and methods” section. The
model does not rely on ﬁxed transi-
tion probabilities.
2. Concerning switching between the
two study arms (adalimumab arm,
control arm): The purpose of having
a control arm is the ability to attribute
clinical and economic eﬀects to the
introduction of adalimumab with the
smallest possible bias. Switching is
impossible by design.
3. Concerning Weber and colleagues’
request for further discussion of var-
ious aspects in their 7500+ character
letter: The journal deserves our grat-
itude for taking into consideration
our 30,000+ character manuscript
despite its 25,000 character limit. We
honored the journal’s brevity require-
ments as much as possible and we
stuck to citations whenever possible.
4. Concerning quality of life: Contrary
to Weber and colleagues’ suggestion,
the absolute levels of quality of life,
which they estimated from [1],
cannot be compared to the relative
gains of quality of life in our model.
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